KMT2A and acute myeloid leukemia: For example, favorable outcomes with a 5-year event free survival (EFS) rate of 92% were observed in pediatric AML patients with t(1:11)(q21;p23) (MLL-AF1q) while poor clinical outcomes were observed for t(6;11)(q27;q23) (MLL-AF6), t(10;11)(p11.2;q23) (MLL-ABI1) and t(4;11)(q21;q23) (MLL-AF4) with EFS rates of 11%, 17% and 29% respectively [2, 3].